Showing 15 posts of 26 posts found.


Top Ten most popular articles on this week!

June 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma

Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …

Otsuka to take over Astellas’ Cefixime business

June 7, 2019
Medical Communications APIs, Antibiotics, Astellas, Otsuka, antimicrobial, pharma

Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime. The agreement gives Otsuka the right to sell Cefixime and …

Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect

February 15, 2019
Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …


Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3

August 1, 2018
Research and Development, Sales and Marketing Astex, Otsuka, Rxulti, guadecitabine, pharma, schizophrenia

It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) …


Otsuka snaps up Visterra in $430 million deal

July 12, 2018
Research and Development, Sales and Marketing Otsuka, Visterra, acquisition, pharma

Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an …

Lundbeck, Otsuka’s trial Alzheimer’s disease drug gets US FDA fast track designation

July 8, 2016
Medical Communications, Research and Development Alzheimer's disease, Lundbeck, Otsuka, US FDA, drug development, drug trial, fast track designation

H. Lundbeck A/S (CPH: LUN) and Otsuka Pharmaceutical said the US Food and Drug Administration (FDA) have granted Fast Track …

Lundbeck HQ

Lundbeck gets go-ahead for US and EU licence expansions

February 4, 2016
Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine

Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …


SMC approves first ever treatment for genetic kidney disease

January 12, 2016
Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan

The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …


Otsuka, GW announce Sativex fails in Phase III cancer pain trials

October 28, 2015
Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure

Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …

Proteus system

US FDA accepts first digital medicine application

September 11, 2015
Medical Communications FDA, NDA, Otsuka, digital, digital medicine, proteus

The FDA has accepted the first New Drug Application for a digital medicine: Otsuka and Proteus Digital Health’s collaboration of …

Rexulti (brexpiprazole)

FDA approves Lundbeck and Otsuka’s Rexulti for depression

July 14, 2015
Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia

Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …

otsuka image

Otsuka, ViiV and AstraZeneca named in ABPI code complaints

May 26, 2015
Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Otsuka, PMCPA, ViiV

A ‘senior male employee’ of Otsuka Pharmaceuticals “potentially brought the industry into disrepute” by plying a female healthcare professional with …

Novartis image

Three drugs put forward for EMA authorisation

March 2, 2015
Research and Development, Sales and Marketing Amgen, EMA, FDA, Novartis, Otsuka, jinarc, ristempa, zykadia

Novartis’ lung cancer drug Zykadia has been recommended for EU approval in patients previously treated with Pfizer’s Xalkori – the …

Sativex image

Late-stage failure for Otsuka and GW cancer pain drug

January 9, 2015
Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols

Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …

AZ image

Pharma to lose $69 billion in five years as patents expire

December 12, 2014
Sales and Marketing AstraZeneca, GlobalData, Japanese firm Otsuka, Otsuka, lilly, pharma

Pharma companies are set to lose around $65 billion by 2019 due to drug patent expiries according to research firm …

Latest content